Login to Your Account

BI Hails F-Star's Fcab Platform in Seven-Target Antibody Deal

By Nuala Moran

Wednesday, November 24, 2010
LONDON – Antibody engineering start-up f-star Biotechnologische GmbH landed its first major partnership, agreeing to an €180 million (US$245.4 million)-per-target deal to apply its modular antibody technology to discover antibodies and/or antibody fragments against seven targets nominated by partner Boehringer Ingelheim GmbH. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription